Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joe Sasadeusz

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2025
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV CoinfectionJennifer Audsley, Anchalee Avihingsanon, Xin Li, et al.
The Lancet. Gastroenterology & Hepatology|November 6, 2018
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trialTarik Asselah, Samuel S Lee, Betty B Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.
Transplantation Direct|September 13, 2021
Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, AustraliaDarren Lee, Indra Gramnea, Nina Seng, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor MalignanciesJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
ASM Case Reports|November 17, 2025
A case of enterovirus D68-associated acute flaccid myelitis in an immunocompromised adult, AustraliaNathaniel Lizak, Grace Butel-Simoes, Eike Steinig, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and ImmunologyJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant RecipientsJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer AgentsJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2025
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV CoinfectionJennifer Audsley, Anchalee Avihingsanon, Xin Li, et al.
The Lancet. Gastroenterology & Hepatology|November 6, 2018
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trialTarik Asselah, Samuel S Lee, Betty B Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.
Transplantation Direct|September 13, 2021
Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, AustraliaDarren Lee, Indra Gramnea, Nina Seng, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor MalignanciesJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
ASM Case Reports|November 17, 2025
A case of enterovirus D68-associated acute flaccid myelitis in an immunocompromised adult, AustraliaNathaniel Lizak, Grace Butel-Simoes, Eike Steinig, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and ImmunologyJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant RecipientsJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer AgentsJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Pageof 7